APYX

Rating neutralAI Memo

Apyx Medical

As of 2026-09-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Test of reaffirmed FY2026 guidance • 2026-12-31

Base target: $3 / p=45% prob

Biggest risk

Q2 still produced a $3.2 million attributable net loss, while operating cash use rose year over year. OEM sales fell 12%, and Apyx expects that segment to decline over time. Corporate overhead also includes salaries, professional fees and stock compensation. SEC Exhibit 99.1 [#10-Q-2026-08-06]

Invalidation

Break below $2 or thesis failure.

What would change my mind?

AYON sales, international generator demand and domestic single-use handpieces drove Q2 Surgical Aesthetics growth; gross margin rose to 63.9% from 62.3%. Sustained utilization could improve operating leverage. SEC Exhibit 99.1

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-29

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

AYON power-liposuction rollout
AYON growth versus cash consumption
AYON sales, international generator demand and domestic single-use handpieces drove Q2 Surgical Aesthetics growth; gross margin rose to 63.9% from 62.3%.

BearKey bullets

AYON placements may not translate into sustained utilization or repeat single-use handpiece sales.
OEM revenue declined 12% in Q2, and management expects continued decline in that segment.
SEC Exhibit 99.1

WatchKey bullets

Test of reaffirmed FY2026 guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=45%)

Target spread vs base: +38% / -45%

Scenario probabilities

Bull Target: $4 (p=25%)Base Target: $3 (p=45%)Bear Target: $2 (p=30%)

Commentary

Company-reported Q2 operating trends were constructive, but coverage is thin. The September 28 anchor of $2.50 is below the prior baseline's September 10 anchor of $2.89; that comparison does not isolate an earnings-day reaction. Current analyst revisions, options skew, short interest and sufficient social-sentiment observations were not supplied; zero sentiment fields denote unavailable data, not neutral measurements.

As of 2026-09-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

AYON power-liposuction rollout
AYON growth versus cash consumption

Scenarios

Bull Target (Scenario probability)

$4 / p=25% prob

Base Target (Scenario probability)

$3 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-09-29 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Test of reaffirmed FY2026 guidance
Apyx reaffirmed FY2026 revenue guidance of $59–60 million after Q2 revenue rose 22% to $13.9 million. The remaining-year test is whether AYON-led Surgical Aesthetics growth offsets declining OEM sales. The August results release was furnished with the 8-K. [#SEC-8K-2026-08-06] SEC Exhibit 99.1
Prob 60.00% • Move 15.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

AYON power-liposuction rollout
2026-12-31
Following expanded FDA 510(k) clearance, Apyx began limited shipments of AYON's reusable power-liposuction handpiece in June. Broader surgeon uptake and repeat handpiece use remain unproven. SEC Exhibit 99.1
Prob 55% • Move 18% • Priced-in 45%

Long-term Catalysts

Months to a year

AYON growth versus cash consumption
2027-06-30
Q2 Surgical Aesthetics revenue grew 28%, but operating cash use increased to $3.5 million. Durable adoption must improve cash generation before management's projected cash runway through 2027 can be treated as secure. SEC Exhibit 99.1
Prob 50% • Move 25% • Priced-in 35%

Risks

AYON placements may not translate into sustained utilization or repeat single-use handpiece sales.
OEM revenue declined 12% in Q2, and management expects continued decline in that segment. SEC Exhibit 99.1
Q2 operating cash use of $3.5 million increased from $1.2 million a year earlier; the projected runway through 2027 depends on uptake and cost control. SEC Exhibit 99.1
The August 7 8-K discusses approval of a share incentive plan; potential dilution warrants monitoring, but the supplied excerpt does not quantify it. [#8-K-2026-08-07]

Peers

Symbol	Summary
BSX	Broad surgical-device commercialization benchmark, not a direct aesthetic-body-contouring peer; its scale and diversification limit valuation read-through.
ECOR	Closer small-cap size, but neuromodulation differs materially from Apyx's surgical-aesthetics products. Neither is a direct operating comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-29

Loading AI feed…

Symbol

Summary

BSX

Broad surgical-device commercialization benchmark, not a direct aesthetic-body-contouring peer; its scale and diversification limit valuation read-through.

ECOR

Closer small-cap size, but neuromodulation differs materially from Apyx's surgical-aesthetics products. Neither is a direct operating comparable.